NCT02955589View on ClinicalTrials.gov

Efficacy and Safety of Oral HBI-8000 in Patients With Relapsed or Refractory Adult T Cell Lymphoma (ATL)

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 30, 2016

Primary Completion Date

December 31, 2018

Study Completion Date

November 30, 2019

Conditions

Adult T-Cell Lymphoma (ATL)

Interventions

DRUG

HBI-8000

Oral, twice weekly

Trial Locations (15)

Unknown

Fukuoka

Isehara

Kagoshima

Miyagi

Miyazaki

Nagasaki

Nagoya

Okinawa

Ōita

Ōmura

Saitama

Sapporo

Suita

Tokyo

Yufu

All Listed Sponsors

collaborator

Iqvia Pty Ltd

INDUSTRY

lead

HUYABIO International, LLC.

INDUSTRY

NCT02955589 - Efficacy and Safety of Oral HBI-8000 in Patients With Relapsed or Refractory Adult T Cell Lymphoma (ATL) | Biotech Hunter | Biotech Hunter